0
0
0
s2sdefault

Several public health and tobacco control groups are upset that Philip Morris International would even consider purchasing a pharmaceutical maker that develops inhaled treatments for respiratory diseases, including the COVID-19 infection. “The acquisition of Vectura, following the recently announced agreement to acquire Fertin Pharma, will position us to accelerate this journey by expanding our capabilities in innovative inhaled and oral product formulations in order to deliver long-term growth and returns,” said Jacek Olczak, PMI’s chief executive officer, in the mentioned press release.